Home|Journals|Articles by Year|Audio Abstracts

Review Article

J App Pharm Sci. 2020; 10(2): 129-146

Recent advancements in Uracil and 5-Fluorouracil hybrids as potential anticancer agents: A Review

Mohit Sanduja, Jyoti Gupta, Tarun Virmani.

Cited by 22 Articles

Cancer is the most dreadful disease and the second main cause of death worldwide. The continuous developments have been going on in order to design potent molecules such that this leading cause of death can be dealt with. In order to decrease the level of toxicity and to improve the selectivity of drugs towards cancer targets, development of hybrid molecules has become the centre of research and scientists are doing timeless efforts to generate such a hybrid which has got no comparison with the previous developments. The heterocyclic moiety Uracil and many of its derivatives were already exposed as promising anti-cancer agents. Moreover, coupling of Uracil and 5-Fluorouracil with different pharmacophores has been proven to be an excellent strategy against cancer. Hence, the present review is an effort to collectively represent all the earlier and recent developments of Uracil and 5-Fluorouracil hybrids reported to have significant anti-cancer profile. Expectantly, we can assure that this article can serve as the basis for further developments in Uracil and 5-Fluorouracil hybrids and will surely motivates the medicinal chemists for producing unique anti-cancer drug.

Key words: Uracil, 5-Fluorouracil, Cancer, Hybrid, Anticancer agents, Cell lines.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.